Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOncology, Basic Science Track

Prognostic value of combined [99m]Tc-MAA-SPECT/CT and [18F]Fluoroethylcholine-PET/CT in patients suffering from advanced hepatocellular carcinoma prior to radioembolization

Alexander Haug, Stefan Weber, Sabrina Hartenbach, Mathias Zacherl, Philipp Paprottka, Reinhold Tiling, Peter Bartenstein, Marcus Hacker, Nathalie Albert and Markus Hartenbach
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 2712a;
Alexander Haug
4Division of Nuclear Medicine Medical University of Vienna Vienna Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Weber
4Division of Nuclear Medicine Medical University of Vienna Vienna Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrina Hartenbach
1Armed Forces Hospital Division of Pathology Ulm Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathias Zacherl
6Department of Nuclear Medicine University of Munich Munich Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Paprottka
7Institute of Radiology University of Munich Munich Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reinhold Tiling
6Department of Nuclear Medicine University of Munich Munich Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bartenstein
2Klinik und Polik.inik fur Nuklearmedizin Munchen Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus Hacker
5Universitatsklinik Fur Radiologie Und Nuklearmediz Wien Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Albert
6Department of Nuclear Medicine University of Munich Munich Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Hartenbach
3Biomedical Imaging and Image Guided Therapy Medical University of Vienna Vienna Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

2712a

Objectives Hepatocellular carcinomas (HCC) are increasingly treated with radioembolization (RE). However, prognostic factors with regard to survival are needed for better patient selection.

Methods 24 patients with advanced HCC underwent MAA-SPECT/CT und FEC-PET/CT prior to RE. We evaluated various uptake parameters, tumor-to-spleen-ratio and volumetric overlap of uptake on MAA-SPECT/CT and FEC-PET/CT using Hermes Hybrid 3D viewer. This data was analyzed with regard to survival. We used ROC analysis, Youden-index, multiple logistic regression analysis and Kaplan-Meier analysis for statistical analysis.

Results All patients died with a median survival of 437±71 days. A high overlap of MAA SPECT/CT and FEC PET/CT was significantly associated with a shorter survival (AUC=0,75; P<0,05). A combination of SUV values, tumor-to-spleen-ratio and volumetric data using multiple logistic regression had an AUC of 0.87 (P=0.004) with a sensitivity of 100%, specificity of 75%, accuracy of 92%, a NPV of 89% and a PPV of 100% (P<0.001). Regression analysis was able to separate patients with regard to prognosis (median survival 531±68 days versus 840±96 days; log rank: 5.7; P=0.017).

Conclusions Patients suffering from advanced HCC and a combination of high overlap of MAA-uptake (as a parameter for high tumor vascularization) and FEC-uptake have a significantly shorter survival as the remaining patients. This finding may aid to enhanced patient selection for RE.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 57, Issue supplement 2
May 1, 2016
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic value of combined [99m]Tc-MAA-SPECT/CT and [18F]Fluoroethylcholine-PET/CT in patients suffering from advanced hepatocellular carcinoma prior to radioembolization
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Prognostic value of combined [99m]Tc-MAA-SPECT/CT and [18F]Fluoroethylcholine-PET/CT in patients suffering from advanced hepatocellular carcinoma prior to radioembolization
Alexander Haug, Stefan Weber, Sabrina Hartenbach, Mathias Zacherl, Philipp Paprottka, Reinhold Tiling, Peter Bartenstein, Marcus Hacker, Nathalie Albert, Markus Hartenbach
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 2712a;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prognostic value of combined [99m]Tc-MAA-SPECT/CT and [18F]Fluoroethylcholine-PET/CT in patients suffering from advanced hepatocellular carcinoma prior to radioembolization
Alexander Haug, Stefan Weber, Sabrina Hartenbach, Mathias Zacherl, Philipp Paprottka, Reinhold Tiling, Peter Bartenstein, Marcus Hacker, Nathalie Albert, Markus Hartenbach
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 2712a;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Basic Science Track

  • Imaging adult glioma with 68Ga-citrate PET/MR
  • Evaluation of L-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of Cancer
  • Pretargeted radioimmunotherapy with 225Ac-proteus-DOTA hapten.
Show more Oncology, Basic Science Track

MTA I: Image-Guided Therapy Posters

  • Texture analysis for FMISO PET/CT in oncology patients receiving extra-beam radiation therapy
  • Internal dosimetry calculation of Cu-64 NOTA trastuzumab in human breast cancer xenograft mouse using Monte Carlo simulation.
Show more MTA I: Image-Guided Therapy Posters

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire